ClinicalTrials.gg
RecruitingNCT06297343MODIFVASCUpdated Nov 24, 2025

Study of the Risk of Ischaemia Following the Creation of an Arteriovenous Fistula

An observational study in Renal Failure, sponsored by GCS Ramsay Santé pour l'Enseignement et la Recherche. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-24.

Sponsored by GCS Ramsay Santé pour l'Enseignement et la Recherche · Observational

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
544
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 107 studies in Renal Insufficiency with a site in France — 13 open to participants now, 16 under way, none of them phase 3. Renal Insufficiency · France.

Planned enrollment
10th of 39
544 · median 186
Started
2025
with 3 others
Observational
39 of 107
9 open now
Primary completion
2027-12
later than 11 of 15 live
Registered
102nd of 107
by date
Lead sponsor
3 of 107
GCS Ramsay Santé pour l'Enseignement et la Recherche

Among the 107 studies in Renal Insufficiency with a site in France, this one is the 10th largest by planned enrollment of the 39 observational ones that give a count, is one of 4 that started in 2025, is one of 39 observational ones, reaches primary completion later than 11 of the 15 other live ones, and was the 102nd registered.

Renal Insufficiency

1,415 studies on the registry are indexed under Renal Insufficiency; 149 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

13 of the 107 studies in Renal Insufficiency with a site in France are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 94 Renal Insufficiency studies recruiting now, 49 (52%) set no upper age limit and 19 (20%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 107 studies in Renal Insufficiency with a site in France, or all of them as a file.
02

Study summary

The purpose of this study is to identify functional vascular changes and clinical factors correlated with the occurrence of short- or medium-term hand ischaemia after arteriovenous fistula creation.

Read the detailed description

This is a non-interventional, prospective, non-randomised, descriptive, single-centre study with no comparator.

The study population will be adult patients with chronic renal failure for whom an arteriovenous fistula has been planned.

Patients requiring the creation of an arteriovenous fistula by the surgeons at Hôpital Privé des Peupliers will be seen beforehand in the usual pre-operative consultation, during which the surgeon will explain the principle of the operation and the expected benefits/risks. On the day of surgery, patients will undergo the surgical procedure to create an arteriovenous fistula and will be discharged the same day. Patients will be reviewed during post-operative follow-up visits at 1, 6 and 12 months as in standard practice. All the data collected in the study were collected in routine medical practice.

03

Conditions studied

  • Renal Failure

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will be adult patients suffering from chronic renal failure for whom the creation of an arteriovenous fistula is planned.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years;
  • Stage 5 chronic kidney disease, on dialysis or not on dialysis;
  • Requiring the creation of an arteriovenous fistula;
  • Membership of a social insurance scheme;
  • Patient having been informed and having formulated his/her oral non-opposition to participate in the research.

Exclusion criteria

Exclusion Criteria:

  • to the proposed surgery ;
  • Reduced in the opinion of the investigator;
  • Medical or biological conditions which, in the opinion of the investigator, could influence the interpretation of the results of the study or the safety of the patient;
  • Patient uncooperative with protocol requirements or unable to attend scheduled visits to the centre;
  • Other surgical or medical intervention planned during the study;
  • Pregnant or likely to be pregnant (of childbearing age, without effective ) or breastfeeding;
  • Participating in another clinical trial, or in a period of exclusion from another clinical trial;
  • Patient under guardianship or deprived of liberty.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
544 participants (estimated)
Patient registry
No

Groups and cohorts

  • Adult patients with chronic renal failure

    Adult patients with chronic renal failure for whom arteriovenous fistula creation is planned

    Procedure: Creation of an arteriovenous fistula

Interventions

  • ProcedureCreation of an arteriovenous fistula

    Patients will undergo the surgical procedure to create an arteriovenous fistula and will be discharged the same day (outpatient care, or an overnight stay in hospital if they live a long way from the hospital, have multiple pathologies or are socially isolated). An arteriovenous fistula is created under local or general anaesthetic. On the day of the operation, the type of arteriovenous fistula created, the side of the arteriovenous fistula, the location of the arteriovenous fistula and the patency of the arteriovenous fistula will be collected.

06

What researchers measure

Primary outcomes

  1. Occurrence of ischaemia of the hand

    Number and proportion of patients with ischaemia (Yes = stages 1, 2 or 3/No = stage 0) according to the preoperative American Vascular Surgery ischaemia classification : 0 - nothing 1. \- cold hand 2. \- pain on exercise and/or during dialysis 3. \- permanent pain, wound (ulceration, necrosis, gangrene)

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Dec 2027, 26 months after the start.

Of 88 non-industry observational studies under Renal Insufficiency, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 58. This study's planned 26 months is below that.

Counting every sponsor, half of 103 studies reached it within 30 months; a quarter within 14 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 29, 2024
First posted
Mar 7, 2024
StartActual
Oct 20, 2025
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Nov 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06297343
Collaborators
Euraxi Pharma
Responsible party
Sponsor
First posted
Mar 7, 2024
Start date
Oct 20, 2025
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 24, 2025

Study contacts

Viviane DUEDAL, MD
Contact
v.duedal@gmail.com
6 70 80 18 98 ext. +33

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion